Cambridge Prisms: Antimicrobial Resistance is dedicated to advancing and accelerating the development, uptake, and adoption of products, processes, and policies to help mitigate the impact of antimicrobial resistance (AMR). Addressing AMR effectively requires an integrated, One Health approach, which recognises that human, animal and environmental health are interconnected. Our primary mission is to serve as an essential platform for the dissemination of high-quality translational and implementation research, innovation, and informed discourse on AMR. Beyond the traditional boundaries of scientific inquiry, the journal aims to foster interdisciplinary collaboration by providing a forum where researchers, clinicians, veterinarians, policymakers, regulators, and industry and business stakeholders converge to share insights that will deliver impact.The journal advocates for increased global efforts to address AMR and protect the efficacy of current and new antimicrobial medicines. We encourage submissions that investigate how and why efforts to curb AMR have, to date, not yielded the expected results. We encourage the generation of evidence for action as well as evidence of action on curbing AMR. Additionally, we seek studies that highlight the need for systems’ level thinking and that provide information to prevent adverse consequences of interventions being shifted from one sector to another.